SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Medivation, Inc.
(Nasdaq: MDVN) today announced it has initiated dosing of patients in its
second pivotal Phase 3 trial of the investigational drug Dimebon(TM) in
patients with mild-to-moderate Alzheimer's disease (AD). The international,
double-blind, placebo-controlled safety and efficacy study of oral Dimebon
is known as the CONNECTION study.

"We saw very encouraging results in our first pivotal trial, in which
Dimebon demonstrated statistically significant improvements over placebo on
all five efficacy endpoints at both six months and at one year. We look
forward to confirming the efficacy and safety of Dimebon in the CONNECTION
study," said Lynn Seely, M.D., Chief Medical Officer of Medivation. "The
initiation of this study brings us a major step closer to our goal of
obtaining regulatory approval for Dimebon. We are working to bring this
investigational drug to market as quickly as possible to address the unmet
medical need in Alzheimer's disease and bring hope to patients and
caregivers."

The U.S. Food and Drug Administration (FDA) has informed Medivation
that the CONNECTION study together with the previously completed pivotal
trial can be used to support the approval of Dimebon to treat
mild-to-moderate Alzheimer's disease, as long as a significant proportion
of the sites in the CONNECTION study are located in the United States.
Medivation expects to complete the CONNECTION study and apply for U.S. and
European marketing approval in 2010.

Design of CONNECTION Study

The CONNECTION study will enroll approximately 525 patients with
mild-to-moderate Alzheimer's disease at approximately 100 sites in the
United States, Europe and South America. Patients will be randomized to one
of three treatment groups: Dimebon 20 mg three times per day, Dimebon 5 mg
three times per day or placebo. Patients may not be taking any other
Alzheimer's disease drugs during the trial. After completing six months of
treatment, all patients -- including those randomized to placebo -- will be
offered the opportunity to receive Dimebon in an extension trial until
marketing authorization.

The primary endpoints of the trial are the Alzheimer's Disease
Assessment Scale -- cognitive subscale (ADAS-cog) and the Clinician's
Interview-Based Impression of Change plus caregiver interview (CIBIC-plus).
These are the two endpoints that have been accepted by the FDA to support
registration of all approved drugs for Alzheimer's disease.

"Currently available therapies for Alzheimer's disease have modest
effects, for the most part," said Pierre Tariot, M.D., Director, Memory
Disorders Center, Banner Alzheimer's Institute. "There is an urgent need
for new treatments for a disease with such devastating effects on the
quality of life of patients and their caregivers. Dimebon represents an
innovative form of therapy that may have the potential to ameliorate
symptoms and possibly improve the course of Alzheimer's disease. It is
crucial that it be fully assessed as rapidly as possible."

Medivation previously announced results from its first pivotal trial of
Dimebon in 183 patients with mild-to-moderate Alzheimer's disease, which
showed that Dimebon improved the clinical course of Alzheimer's disease by
demonstrating statistically significant improvements over placebo in each
of the five primary aspects of the disease -- memory, thinking, activities
of daily living, behavior and overall clinical function. Significant gains
over placebo were evident after as little as 12 weeks of treatment, and
were maintained after both six months and a full year of treatment.
Importantly, overall benefit compared to placebo continued to increase over
time, and was larger at one year than at six months. Dimebon was
well-tolerated throughout the entire one-year treatment period. The
majority of adverse events were mild. Dry mouth (18.0 percent Dimebon, 1.1
percent placebo) and depressed mood were the most common events. Patients
treated with Dimebon experienced significantly fewer serious adverse events
than those treated with placebo at one year.

About Dimebon

Dimebon is an orally-available small molecule that has been shown to
inhibit brain cell death in preclinical models relevant to Alzheimer's
disease and Huntington's disease, making it a potential treatment for these
and other neurodegenerative diseases. Preclinical data generated to date
suggest that Dimebon operates through a novel mitochondrial mechanism of
action.

Medivation is also evaluating Dimebon in an ongoing Phase 2 clinical
trial in Huntington's disease.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid
development of novel small molecule drugs to treat serious diseases of the
central nervous system and cancers for which there are limited treatment
options. Medivation aims to revolutionize the treatment of these diseases
and offer hope to critically ill patients and their caregivers. The
Company's current clinical development program includes a pivotal and
confirmatory Phase 3 trial of Dimebon(TM) in Alzheimer's disease, a Phase 2
clinical trial of Dimebon in patients with Huntington's disease, and a
Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant
(also known as hormone-refractory) prostate cancer. For more information,
please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including
statements regarding anticipated clinical and regulatory milestones, which
are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements involve risks and
uncertainties that could cause actual results to differ significantly from
those projected. You are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date of this
release. None of the Company's product candidates has been approved for
sale, significant additional animal and human testing is required in order
to seek marketing approval for any of its product candidates, and
Medivation cannot assure you that marketing approval can be obtained for
any of its product candidates. Furthermore, as is typically the case at
this stage of the regulatory review process, the FDA has not yet performed
an in-depth review of Medivation's preclinical and clinical data, so its
views remain subject to change. Medivation's filings with the Securities
and Exchange Commission, including its Annual Report on Form 10-KSB for the
year ended December 31, 2007, and its Quarterly Report on Form 10-Q for the
quarter ended March 31, 2008, include information about additional factors
that could affect the Company's financial and operating results.

(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...

(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and ... Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD ... that can be easily incorporated into liquid products, while reducing costs to end users. ...

(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...

(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...

(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...